Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial - PubMed

Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial

H Jürgens et al. Cancer. 1988.

Abstract

The German Society of Pediatric Oncology in 1981 initiated the Cooperative Ewing's Sarcoma Study (CESS 81) using a four-drug combination of chemotherapy prior to definitive local control with surgery and/or radiation. From January 1, 1981 until February 28, 1985, 93 patients were registered at the trial office from 54 participating institutions in West Germany, Austria, Switzerland, and the Netherlands. On February 1, 1987, 54 of 93 patients were disease-free. Using the Kaplan-Meier life table analysis, the estimated disease-free survival (DFS) rate was 60% at 36 months and 55% at 69 months. The median period of observation was 29 months, ranging from 22 months to 69 months. Twenty-one of 93 patients (23%) had local failure, 18 of 93 patients (19%) developed systemic metastases. The local failure rate was particularly high in patients treated with radiation and was reduced when radiation planning was centralized within the study based upon the extent of disease at diagnosis. Cox regression analysis of prognostic factors showed that tumor volume was a significant factor influencing prognosis. The estimated 3-year DFS rate was 80% for patients with small tumors (volume less than 100 ml) compared to 31% for patients with large tumors (volume greater than or equal to 100 ml). In patients who had surgery for local control, the histologic response to chemotherapy was analyzed on the surgical specimen and had a strong influence on survival: 79% DFS at 3 years for patients with less than 10% viable tumor (good responders) compared to 31% DFS for patients with more than 10% viable tumor (poor responders). Tumor load and responsiveness to chemotherapy are the two major factors influencing prognosis in patients with primary Ewing's sarcoma of bone.

Similar articles

• Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.

  Andreou D, Ranft A, Gosheger G, Timmermann B, Ladenstein R, Hartmann W, Bauer S, Baumhoer D, van den Berg H, Dijkstra PDS, Dürr HR, Gelderblom H, Hardes J, Hjorth L, Kreyer J, Kruseova J, Leithner A, Scobioala S, Streitbürger A, Tunn PU, Wardelmann E, Windhager R, Jürgens H, Dirksen U; GPOH-Euro-EWING99 consortium. Andreou D, et al. Clin Orthop Relat Res. 2020 Feb;478(2):290-302. doi: 10.1097/CORR.0000000000000962. Clin Orthop Relat Res. 2020. PMID: 31580267 Free PMC article.

• Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study.

  Ahrens S, Hoffmann C, Jabar S, Braun-Munzinger G, Paulussen M, Dunst J, Rübe C, Winkelmann W, Heinecke A, Göbel U, Winkler K, Harms D, Treuner J, Jürgens H. Ahrens S, et al. Med Pediatr Oncol. 1999 Mar;32(3):186-95. doi: 10.1002/(sici)1096-911x(199903)32:3<186::aid-mpo5>3.0.co;2-d. Med Pediatr Oncol. 1999. PMID: 10064186 Clinical Trial.

• Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group.

  Cotterill SJ, Ahrens S, Paulussen M, Jürgens HF, Voûte PA, Gadner H, Craft AW. Cotterill SJ, et al. J Clin Oncol. 2000 Sep;18(17):3108-14. doi: 10.1200/JCO.2000.18.17.3108. J Clin Oncol. 2000. PMID: 10963639

• Ewing's sarcoma. Prognostic factors, disease control, and the reemerging role of surgical treatment.

  O'Connor MI, Pritchard DJ. O'Connor MI, et al. Clin Orthop Relat Res. 1991 Jan;(262):78-87. Clin Orthop Relat Res. 1991. PMID: 1984935 Review.

• Primary cutaneous Ewing sarcoma: a systematic review focused on treatment and outcome.

  Delaplace M, Lhommet C, de Pinieux G, Vergier B, de Muret A, Machet L. Delaplace M, et al. Br J Dermatol. 2012 Apr;166(4):721-6. doi: 10.1111/j.1365-2133.2011.10743.x. Epub 2012 Mar 5. Br J Dermatol. 2012. PMID: 22098102 Review.

Cited by

• A rare case of primary Ewings sarcoma of the nasal bone.

  Vidyasagar MS, Rao S, Fernandes DJ, Ramanujam AS. Vidyasagar MS, et al. Indian J Otolaryngol Head Neck Surg. 1998 Jan;50(1):69-72. doi: 10.1007/BF02996777. Indian J Otolaryngol Head Neck Surg. 1998. PMID: 23119384 Free PMC article.

• Long term survival after heart transplantation for doxorubicin induced cardiomyopathy.

  Aricò M, Pedroni E, Nespoli L, Viganò M, Porta F, Burgio GR. Aricò M, et al. Arch Dis Child. 1991 Aug;66(8):985-6. doi: 10.1136/adc.66.8.985. Arch Dis Child. 1991. PMID: 1929498 Free PMC article.

• Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches.

  Campbell K, Shulman D, Janeway KA, DuBois SG. Campbell K, et al. Sarcoma. 2018 Aug 8;2018:1712964. doi: 10.1155/2018/1712964. eCollection 2018. Sarcoma. 2018. PMID: 30158829 Free PMC article.

• Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone.

  Ataergin S, Ozet A, Solchaga L, Turan M, Beyzadeoglu M, Oysul K, Arpaci F, Komurcu S, Surenkok S, Ozturk M. Ataergin S, et al. Med Oncol. 2009;26(3):276-86. doi: 10.1007/s12032-008-9115-6. Epub 2008 Nov 7. Med Oncol. 2009. PMID: 18989798

• Prediction of response and prognostic factors for Ewing family of tumors in a low incidence population.

  Yonemori K, Yamaguchi U, Kaneko M, Uno H, Takeuchi M, Ando M, Fujiwara Y, Hosono A, Makimoto A, Hasegawa T, Yokoyama R, Nakatani F, Kawai A, Beppu Y, Chuman H. Yonemori K, et al. J Cancer Res Clin Oncol. 2008 Mar;134(3):389-95. doi: 10.1007/s00432-007-0295-9. Epub 2007 Aug 9. J Cancer Res Clin Oncol. 2008. PMID: 17687565

Publication types

MeSH terms

LinkOut - more resources

• Medical

  • MedlinePlus Health Information